Shop / Retatrutide
For laboratory research use only
Triple Metabolic Agonist
Retatrutide
10mg · Lyophilised Powder
$159.00
Retatrutide is a triple receptor agonist at GIP, GLP-1, and glucagon — the most comprehensive metabolic targeting available in peptide research. It addresses the multi-hormonal drivers of weight resistance and metabolic dysfunction that women face through perimenopause.
Key Highlights
10mg Retatrutide per vial — lyophilised for stability
≥99% purity, HPLC-verified
Triple GIP/GLP-1/Glucagon receptor agonist
Studied in models of weight regulation and metabolic health
Most comprehensive receptor profile in metabolic peptide research
Sterile glass vial, GMP-certified manufacture
Why This Compound Matters for Women
Retatrutide represents the frontier of metabolic peptide research. Unlike single or dual agonists, it simultaneously targets three key receptor systems: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This triple agonism creates a more comprehensive metabolic effect than prior-generation compounds — addressing not only glucose and insulin regulation but also energy expenditure and fat mobilisation. For women, this is significant because the metabolic challenges of perimenopause are multi-factorial: declining oestrogen increases insulin resistance, shifts fat distribution toward the abdomen, reduces resting energy expenditure, and impairs the hormonal signals that govern appetite and satiety. No single receptor pathway addresses all of these simultaneously. Retatrutide, in research models, has demonstrated effects across weight reduction, metabolic rate improvement, and glucose regulation that position it as one of the most promising compounds for female metabolic health in the current research landscape.
Research Areas
For research context only. All applications are laboratory use.
GLP-1 Receptor Agonism
GLP-1 agonism is studied for its effects on insulin secretion, appetite regulation, and gastric emptying — mechanisms that become progressively dysregulated in women through perimenopause.
GIP Receptor Targeting
GIP receptor activity is investigated for its role in insulin sensitivity and fat storage regulation — adding a dimension of metabolic influence that single GLP-1 agonists do not provide.
Glucagon Receptor Activation
Glucagon receptor agonism increases energy expenditure and promotes fat oxidation — addressing the metabolic rate reduction that many women experience as oestrogen declines.
Weight Regulation & Body Composition
Pre-clinical and early clinical research on Retatrutide has explored significant effects on body weight and composition — positioning it as a compelling area of investigation for hormonal weight resistance in women.
Specifications
Research Use Only. Not intended for human or veterinary use. Handle with sterile technique. Store refrigerated between 2–8°C.